
Richard Wyatt Childs MD
"Senior Investigator,Laboratory of Transplantation Immunotherapy\rRear
Join to view full profile
10 Center DrBldg 10, Crc Room 3e-5330Bethesda, MD 20892
Phone+1 301-594-8008
Fax+1 301-480-2664
Join Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 6 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Richard Childs, MD is a hematologist in Bethesda, Maryland.
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 1995 - 1998
University of FloridaResidency, Internal Medicine, 1991 - 1995
Georgetown University School of MedicineClass of 1992
Certifications & Licensure
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an "outpatient" alemtuzumab, fludarabine-based reduced intensity allogen...Phuong Vo, Ramaprasad Srinivasan, Enkhtsetseg Purev, Emily McDuffee, Tatyana Worthy
Bone Marrow Transplantation. 2024-12-01 - Quantification of circulating TCR-engineered T cells targeting a human endogenous retrovirus post-adoptive transfer using nanoplate digital PCR.Stefan Barisic, Elena Cherkasova, Rosa Nadal, Xin Tian, Long Chen
Molecular Therapy. Methods & Clinical Development. 2024-09-12 - 10 citationsRegression of renal cell carcinoma by T cell receptor-engineered T cells targeting a human endogenous retrovirus.Stefan Barisic, Elizabeth M Brahmbhatt, Elena Cherkasova, Timothy T Spear, Ujjawal Savani
Journal for Immunotherapy of Cancer. 2024-09-11
Press Mentions
FDA Approves First Stem Cell Therapy to Treat Severe Aplastic AnemiaDecember 8th, 2025
Gamida Cell Presents Positive Initial Results on Treating Severe Aplastic Anemia (SAA) with OmidubicelOctober 28th, 2025
Blood Test May Identify Patients with AML at Greater Risk of Relapse After Bone Marrow TransplantMarch 9th, 2023









